Faron Pharmaceuticals Ltd

About Faron Pharmaceuticals Ltd

Faron Pharmaceuticals Ltd is a global, clinical-stage biopharmaceutical company focused on developing innovative cancer treatments that leverage the patient's immune system. Their mission is to address unmet medical needs in cancer and improve patient lives through breakthrough immunotherapies.

Products & Services

Bexmarilimab:A first-in-class anti-Clever-1 antibody, currently in Phase I/II clinical trials as a potential therapy for hematological cancers in combination with standard treatments. It aims to enhance the efficacy of cancer treatments for both solid tumors and hematologic malignancies.

Specialties

Immunotherapy Cancer Treatment Macrophage-Targeting Therapies Hematological Cancers Solid Tumors

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Placing (Equity Financing) T: - FT: Placing (Equity Financing)	A: 7526000 MR: - FA: approximately EUR 7.1 million FAN: 7526000	D: 2023-10-27 FD: 2023-10-27	3 investors

Placing (Equity Financing) Latest

2023-10-27

$7.5M

3 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

T

Toni Choueiri

Professor of Medicine at Harvard Medical School

T

Tom Powles

Professor, Barts Cancer Center, London

A

Amer Zeidan

Professor of Medicine

N

Naval G. Daver

Professor

M

Mika Kontro

Adjunct Professor, HUS, CCC

C

Cristophe Massard

Professor, Gustave Roussy CCC, Paris

View 16 more team members with Pro

Unlock Full Team Directory

Recent News